Rafferty Asset Management’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
Rafferty Asset Management's BEAM Position: Q1 2026 in Review
Rafferty Asset Management reduced its Beam Therapeutics (BEAM) stake by 2.2% in Q1 2026, selling an estimated $109K and leaving 172,948 shares worth $4.12M. The position accounts for 0.02% of the portfolio, ranked #452.
Rafferty Asset Management first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $9.25M in Q4 2023. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- Rafferty Asset Management held 172,948 shares of Beam Therapeutics worth $4.12M as of Q1 2026.
- Rafferty Asset Management sold 3,911 Beam Therapeutics shares in Q1 2026, an estimated $109K.
- Beam Therapeutics made up 0.02% of Rafferty Asset Management's portfolio in Q1 2026, its #452 holding.
- Rafferty Asset Management first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
- Rafferty Asset Management's Beam Therapeutics position peaked at $9.25M in Q4 2023.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.